series-a
Stage
1
Investors
About
MercyBio develops blood-based early cancer detection tests using their patented Mercy Halo™ platform, which leverages extracellular vesicles and low-cost qPCR technology to identify cancer-associated biomarkers with high sensitivity and specificity.
Explore MercyBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.